Hormone receptor (HR)‐positive, human epidermal growth factor receptor 2 (HER2)‐negative tumors account for approximately two thirds of newly diagnosed breast cancer cases, some of which are effectively managed after surgical resection with endocrine therapy alone.1 Here, ERBB2 is linked to breast cancer.